Capricor Therapeutics, Inc.

NasdaqCM:CAPR 주식 보고서

시가총액: US$351.6m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Capricor Therapeutics 관리

관리 기준 확인 4/4

Capricor Therapeutics' CEO는 Linda Marbán, Jan2010 에 임명되었습니다 의 임기는 14.42 년입니다. 총 연간 보상은 $ 747.32K, 29.5% 로 구성됩니다. 29.5% 급여 및 70.5% 보너스(회사 주식 및 옵션 포함). 는 $ 965.70K 가치에 해당하는 회사 주식의 0.62% 직접 소유합니다. 965.70K. 경영진과 이사회의 평균 재임 기간은 각각 12.3 년과 10.6 년입니다.

주요 정보

Linda Marbán

최고 경영자

US$747.3k

총 보상

CEO 급여 비율29.5%
CEO 임기14.7yrs
CEO 소유권0.6%
경영진 평균 재임 기간12.5yrs
이사회 평균 재임 기간10.8yrs

최근 관리 업데이트

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Recent updates

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Sep 18
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Jul 30
Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Feb 01
Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Oct 14
We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result

Sep 25

Capricor Therapeutics slumps 9% on $75M stock offering

Jun 21

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

May 16
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

CEO 보상 분석

Linda Marbán 의 보수는 Capricor Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$747kUS$221k

-US$22m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$210k

-US$29m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$23m

Dec 31 2021US$2mUS$200k

-US$20m

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$2mUS$150k

-US$14m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$229kUS$157k

-US$8m

Sep 30 2019n/an/a

-US$9m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$377kUS$233k

-US$15m

Sep 30 2018n/an/a

US$374k

Jun 30 2018n/an/a

US$2m

Mar 31 2018n/an/a

US$2m

Dec 31 2017US$602kUS$233k

US$2m

보상 대 시장: Linda 의 총 보상 ($USD 747.32K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.51M ).

보상과 수익: Linda 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Linda Marbán (61 yo)

14.7yrs

테뉴어

US$747,315

보상

Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be...

리더십 팀

이름위치테뉴어보상소유권
Frank Litvack
Executive Chairman of the Board12.7yrsUS$759.55k0.38%
$ 1.3m
Linda Marbán
Co-Founder14.7yrsUS$747.32k0.56%
$ 2.0m
Anthony Bergmann
CFO & Corporate Treasurer6.7yrsUS$730.85k0.0067%
$ 23.7k
Karen Krasney
Executive VP12.5yrsUS$740.77k0.057%
$ 199.5k
Kristi A. Elliott
Chief Science Officerno data데이터 없음데이터 없음
Catherine Kelleher
Consultantno data데이터 없음데이터 없음

12.5yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 관리: CAPR 의 관리팀은 노련하고 경험 (평균 재직 기간 12.3 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Frank Litvack
Executive Chairman of the Board12.7yrsUS$759.55k0.38%
$ 1.3m
Linda Marbán
Co-Founder10.8yrsUS$747.32k0.56%
$ 2.0m
George Dunbar
Independent Director10.8yrsUS$211.13k0.030%
$ 105.0k
Earl Collier
Independent Director10.8yrsUS$222.37k0.16%
$ 565.7k
David Musket
Independent Director10.8yrsUS$237.36k0.25%
$ 883.4k
Francesco Muntoni
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Pat Furlong
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Eugenio Mercuri
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Craig McDonald
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Oscar Mayer
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Michelle Eagle
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Michael Taylor
Member of Scientific Advisory Board6.7yrs데이터 없음데이터 없음

10.8yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: CAPR 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.6 년).